

Publikační činnost Kliniky hematologie za rok 2017

Publikace in extenso:

Články v časopisech s IF

1. **Hájek R**, Masszi T, Petrucci MT, Palumbo A, Rosiňol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górník S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). *Leukemia*. 2017 Jan;31(1):107-114. IF 11,702
2. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, **Hájek R**, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiňol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. *Leukemia*. 2017 Jan;31(1):115-122. IF 11,702
3. Všíanská P, Bezděková R, Kryukov F, Almáši M, Pour L, Penka M, **Hájek R**, Říhová L. Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors. *Eur J Haematol*. 2017 Jan;98(1):19-25. IF 2.653
4. Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, **Hájek R**, Rosiňol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. *Blood Cancer J*. 2017 Apr 21;7(4):e554. IF 6,126
5. Steiner N, Borjan B, **Hájek R**, Jöhner K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G. Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. *Oncotarget*. 2017 Apr 21;8(34):56243-56254. IF 5,168
6. Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, **Hájek R**, Rosiňol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. *Br J Haematol*. 2017 May;177(3):404-413. IF 5,67
7. Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiňol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, **Hájek R**.

- Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. *Leukemia*. 2017 Jun;31(6):1368-1374. IF 11,702
8. Steiner N, **Hajek R**, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Untergasser G, Gunsilius E. High levels of FLT3 ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. *PLoS One*. 2017 Jul 20;12(7):e0181487. IF 2,806
 9. Thomsen H, Campo C, Weinhold N, da Silva Filho MI, Pour L, Gregora E, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, **Hajek R**, Goldschmidt H, Hemminki K, Försti A. Genomewide association study on monoclonal gammopathy of unknown significance (MGUS). *Eur J Haematol*. 2017 Jul;99(1):70-79. IF 2,653
 10. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, **Hajek R**, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017 Jul 1;28(suppl_4):iv52-iv61. IF 11,855
 11. Sandecká V, **Hájek R**, Pour L, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, **Zahradová L**, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, Wróbel M, Brožová L, Jarkovský J, Mikulášová A, Říhová L, Ševčíková S, Straub J, Minařík J, Adam Z, Krejčí M, Král Z, Maisnar V; Czech Myeloma Group. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. *Eur J Haematol*. 2017 Jul;99(1):80-90. IF 2,653
 12. Sezer O, Beksac M, **Hajek R**, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbaz Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. *Br J Haematol*. 2017 Jul;178(1):61-71. IF 5,67
 13. Castillo JJ, Jurczynszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, **Hajek R**, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM myeloma: A multicenter retrospective study of 134 patients. *Am J Hematol*. 2017 Aug;92(8):746-751. IF 5,275
 14. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, **Hajek R**, Palumbo A, Boccadoro M. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed youngmyeloma patients: a pooled analysis. *Leukemia*. 2017 Aug;31(8):1727-1734. IF 11,702
 15. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, **Hájek R**, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg

- D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Br J Haematol*. 2017 Aug;178(4):571-582. IF 5,67
16. Grzasko N, **Hajek R**, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczynszyn A, Korpysz M, Dmoszynska A. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. *Leuk Lymphoma*. 2017 Sep;58(9):1-15. IF 2,755
17. Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, **Kufova Z**, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, **Hajek R**, Davies FE, Morgan GJ, Walker BA. The spectrum of static mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. *Haematologica*. 2017 Sep;102(9):1617-1625. IF 7,702
18. Sedlarikova L, Gromesova B, Kubackzova V, Radova L, **Filipova J**, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, Bezdekova R, Stork M, Adam Z, Pour L, Krejci M, Kuglík P, **Hajek R**, Sevcikova S. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. *Eur J Haematol*. 2017 Sep;99(3):223-233. IF 2,653
19. **Ševčíková T**, **Growková K**, **Kufová Z**, **Filipová J**, Vrublová P, **Jelínek T**, **Kořístek Z**, Kryukov F, Kryukova E, **Hájek R**. Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. *J Clin Pathol*. 2017 Oct;70(10):847-853. IF 2,687
20. Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, **Hájek R**, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. *Leuk Lymphoma*. 2017 Oct;58(10):2501-2504. IF 2,755
21. **Jelinek T**, Bezdekova R, **Zatopkova M**, Burgos L, **Simicek M**, **Sevcikova T**, Paiva B, **Hajek R**. Current applications of multiparameter flow cytometry in plasma cell disorders. *Blood Cancer J*. 2017 Oct 20;7(10):e617. IF 6,126
22. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, **Hajek R**, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2017 Oct;18(10):1327-1337. IF 33,9
23. **Jelinek T**, **Mihalyova J**, **Kascak M**, **Duras J**, **Hajek R**. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. *Immunology*. 2017 Nov;152(3):357-371. IF 3,701
24. **Jelínek T**, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Adamová D, Wróbel M, Mikula P, Jarkovský J, Diels J, Gatopoulou X,

- Veselá Š, Besson H, Brožová L, Ito T, **Hájek R**. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. *Curr Med Res Opin*. 2017 Nov 25;1-20. IF2,757
25. **Growková K**, Kryukova E, **Kufová Z**, **Filipová J**, **Ševčíková T**, Říhová L, **Kaščák M**, Kryukov F, **Hájek R**. Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. *Eur J Haematol*. 2017 Dec;99(6):469-478 IF 2,653
26. Lobello Cosimo, Janikova Andrea, Kren Leos, Hermanová Markéta, Sprlakova-Puková Andrea, Krejci Jan, Pospisilova Sarka, Pytlik Robert, Hamouzova Michaela, Belada David, Prochazka Vit, **Duras Juraj**, Mocikova Heidi and Trneny Marek. An anaplastic cardiac large cell lymphoma: A case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin's lymphoma from the Czech Lymphoma Study Group (CLSG) database. *J Cancer Res Ther*. 2017, 5(10):66-71 IF 0,750
27. Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, **Hajek R**, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. *Leukemia*. 2017 Dec;31(12):2630-2641. IF 11,702
28. **Jelínek T**, Kryukova E, Kufova Z, Kryukov F, **Hajek R**. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. *Hematol Oncol*. 2017 Dec;35(4):408-419. IF 3,118
29. ČOMA, M., **Elena TÓTHOVÁ**, T. GUMAN, M. HÁJIKOVÁ, M. GIERTLOVÁ a M. ŠARIŠSKÝ. Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia. *Leukemia & lymphoma*. 2017, 58(7): 1726-1729. IF 2,755

Články v recenzovaných časopisech

1. **Jelínek T**, Kořístka M, Čermáková Z, **Hájek R**. Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories. *Klin Onkol*. Winter 2017;30(1):13-19.
2. Almasi M, Sevcikova S, Penka M, Krejci M, Adam Z, Vrublova P, **Jelínek T**, **Hájek R**. Biobanking - the First Step to Successful Liquid Biopsy Experiments. *Klin Onkol*. 2017 Summer;30 (Supplementum 2):9-12.
3. Říhova L, Vsianska P, Bezdekova R, Kralova R, Penka M, Krejci M, Pour L, **Hájek R**. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry. *Klin Onkol*. 2017 Summer;30 (Supplementum 2):21-28.
4. Bezdekova R, Penka M, **Hájek R**, Říhova L. Circulating Plasma Cells in Monoclonal Gammopathies. *Klin Onkol*. 2017 Summer;30 (Supplementum 2):29-34.

5. Maluskova D, Svobodová I, Kucerova M, Brozova L, Muzik J, Jarkovský J, **Hájek R**, Maisnar V, Dusek L. Epidemiology of Multiple Myeloma in the Czech Republic. *Klin Onkol.* 2017 Summer;30 (Supplementum2):35-42.
6. Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, Jarkovský J, Němec P, Horinek D, Stefanikova Z, Pour L, **Hájek R**, Maisnar V. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation. *Klin Onkol.* 2017 Summer;30 (Supplementum 2):43-50.
7. Brozova L, Jarkovský J, Pour L, Minárik J, Jungová A, Gregora E, Spicka I, Maisnar V, **Hájek R**. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies. *Klin Onkol.* 2017 Summer;30 (Supplementum 2):51-59.
8. **Kufová Z, Sevcikova T, Growkova K**, Vojta P, **Filipová J**, Adam Z, Pour L, Penka M, Rysava R, Němec P, Brozova L, Vychytilova P, Jurczyszyn A, Grosicki S, Barchnicka A, Hajdúch M, **Simicek M, Hájek R**. Biomarkers in Immunoglobulin Light Chain Amyloidosis. *Klin Onkol.* 2017 Summer;30 (Supplementum 2):60-67.
9. **M Simicek M, Growkova K, Hájek R**. CRISPR in Research and Treatment of Multiple Myeloma. *Klin Onkol.* 2017 Summer;30 (Supplementum 2):68-74.
10. **Zatopkova M, Filipová J, Jelínek T**, Vojta P, **Sevcikova T, Simicek M**, Rihova L, Bezdekova R, **Growkova K, Kufová Z**, Smejkalová J, Hajdúch M, Pour L, Minárik J, Jungová A, Maisnar V, Kryukov F, **Hájek R**. Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease. *Klin Onkol.* 2017 Summer;30 (Supplementum 2):75-80.
11. **Growkova K, Kufová Z, Sevcikova T, Filipová J, Kascak M, Jelínek T**, Grosicki S, Barchnicka A, Roziaková Ľ, Mistrík M, **Simicek M, Hájek R**. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring. *Klin Onkol.* 2017 Summer;30 (Supplementum 2):81-91.
12. Trávníková M, **Gumulec J, Kořístek Z, Navrátil M**, Janáč M, Pelková J, Šuráň P, Doležálková E, Šimetka O. HELLP syndrome requiring therapeutic plasma exchange due to progression to multiple organ dysfunction syndrome with predominant encephalopathy, respiratory and renal insufficiency. *Ceska Gynekol.* 2017 Summer;82(3):202-205.
13. Blatný J., Blažek B., Čermáková Z., Černá Z., Ďulíček P., Hak J., Hluší A., Hrdličková R., Komrska V., Ovesná P., Pospíšilová D., Procházková D., Smejkal P., Šlechtová J., Timr P., Ullrychova J., Vonke I., Walterová L., Penka M., Zavřelová J., **Gumulec J., Kořístek Z.**, Hajšmanová Z. DIAGNOSTIKA A LÉČBA ZÍSKANÉ HEMOFILIE – KONSENZUÁLNÍ DOPORUČENÍ ČESKÉHO NÁRODNÍHO HEMOFILICKÉHO PROGRAMU (ČNHP) *Transfuze a hematologie dnes.* 2017, roč. 23, č. 2, s. 101-109. ISSN: 1213-5763; 1805-4587 (elektronická verze).
14. KOZÁK, T., J. ČERMÁK, L. ČERVINEK, A. HLUŠÍ, E. KONÍŘOVÁ, M. KOŠŤÁL, J. MAALOUFOVÁ SOUKUPOVÁ, D. POSPÍŠILOVÁ, P. SMÍŠEK, V. VOZOBULOVÁ, O. ČERNÁ a **Jaromír GUMULEC**. Doporučení ČHS pro diagnostiku a léčbu imunitní trombocytopenie (ITP). *Transfuze a hematologie dnes.* 2017, roč. 23, č. 3, s. 158-169. ISSN 1213-5763.

15. **HÁJEK, Roman**. Bezdůvodný rozruch, nebo neuvěřitelný progres?. *Remedia*. 2017, roč. 27, č. 5, s. 470. ISSN 0862-8947.
16. **KUŠNIEROVÁ, Pavlína, David ZEMAN, Radka ŠIGUTOVÁ, Zdeněk ŠVAGERA, Lenka ZHRADOVÁ a Roman HÁJEK**. Obtížně interpretovatelné nálezy elektroforéz a imunofixací u pacientů s mnohočetným myelomem po autologní transplantaci. *Klinická biochemie a metabolismus*. 2017, roč. 25, č. 2, s. 59-63. ISSN 1210-7921.
17. **WEINBERGEROVÁ, B., P. ČIČÁTKOVÁ, M. PALOVÁ, Lukáš STEJSKAL, P. BĚLOHLÁVKOVÁ, J. KISSOVÁ, L. WALTEROVÁ, H. FRAŇKOVÁ, O. ČERNÁ, L. LAKOMÁ, M. BREJCHA, J. PELKOVÁ, M. SCHÜTZOVÁ, J. OBERNAUEROVÁ, D. NECHVÍLOVÁ, E. BOGOCZOVÁ, A. HLUŠÍ, E. FABER, M. PENKA, Y. BRYCHTOVÁ, L. ČERVINEK, M. DOUBEK, P. ŽÁK, J. MAYER a Z. RÁČIL**. Zkušenosti s léčbou ruxolitinem u pacientů s myelofibrózou a pravou polycytemií na českých hematologických pracovištích. *Transfuze a hematologie dnes*. 2017, roč. 23, č. 1, s. 30-40. ISSN 1213-5763.
18. **Plonková H., Jelínek T., Szeligová L., Hájek R.** První perorální inhibitor proteazomu v léčbě relaxujícího/refrakterního mnohočetného myelomu. *Transfuze a hematologie dnes*. 2017, roč. 23, č. 4, s. 199-209. ISSN 1213-5763.

Články v ostatních časopisech

1. Tóthová Elena. Ph-(BCR-ABL1)-negativne myeloproliferativne neopláče-súčasny pohľad na diagnostiku a liečbu. *Postgraduálna medicína* 2017, ročník 19, č.5, s. 9-17
2. **Juraj Ďuraš, Michal Kaščák, Milan Navrátil, Roman Hájek**. Lymfomy z B-buněk marginální zóny. *Onkológia (Bratisl.)*, 2017; roč. 12(5): 344-349.
3. MUDr. **Petra Richterová**, MUDr. **Zdeněk Kořístek**, Ph.D., MUDr. **Lukáš Stejskal**, prof. MUDr. **Roman Hájek**, CSc. OPTIMÁLNÍ LÉČEBNÉ POSTUPY U PACIENTŮ S MYELOYDYSPLASTICKÝM SYNDROMEM. *Onkologická revue*. 2017, roč. 2017, č. 2, s. 17-26.
4. MUDr. **Zdeněk Kořístek**, Ph.D. | MUDr. **Petra Richterová**. Necytostatická kombinace kyseliny all-trans-retinové a oxidu arsenitého v terapii nově diagnostikované akutní promyelocytární leukemie. *Acta medicae*. 2017, roč. 6, č. 3, s. 80-84. ISSN: 1805-398X.
5. **Hájek Roman, Jelínek Tomáš**. Současný algoritmus léčby nemocných s mnohočetným myelomem – kam kráčí? *Acta medicae*. 2017, roč. 6, č. 7-8, s. 88-92. ISSN: 1805-398X.
6. **Juraj Ďuraš, Michal Kaščák, Milan Navrátil, Roman Hájek**. Pixantron v léčbě non-Hodgkinských lymfomů. *Onkologická revue*. 2017, roč. 2017, č. 2, s. 4-9.
7. **Jana Zuchnická, Jana Fečková Mihályová, Juraj Ďuraš, Roman Hájek**. Obinutuzumab v léčbě nemocných s chronickou lymfocytární leukémií a s folikulárním lymfomem. *Onkologická revue*. 2017, roč. 2017, č.3, s.6-10.

8. **Lenka Szeligová, Hana Plonková, Tomáš Jelínek, Roman Hájek.** Mnohočetný myelom a diferenciální diagnostika bolestí páteře. *Onkologie* 2017; 11(6): 300-305

Přednášky:

Přednášky (zahraniční konference)

1. **Roman Hájek.** Transplant Not-eligible Patients . 7th Conference "CURRENT & FUTURE PERSPECTIVES OF MM & other hematological malignancies treatment", 2/2017, Warsaw, Poland
2. **Roman Hájek.** Co-chair of the Oral Session: Genomics and Disease Evolution. 16th International Myeloma Workshop. 3/2017, Dillí, India
3. **Roman Hájek.** Current and future role of MRD in multiple myeloma: guidelines and real-life. „Hematology – how to treat ...in 2017”. 4/2017, Wroclaw, Poland
4. **Roman Hájek.** Current and future treatment options for Multiple Myeloma, focus to relaps/ refractory. Ninlaro Deep Dive Medical Training, 4/2017, Bratislava, Slovak Republic
5. **Roman Hájek.** Single vs. double transplantation. 6th Heidelberg MYELOMA WORKSHOP “Current status and developments in diagnosis and therapy of multiple myeloma”. 5/2017, Heidelberg, Germany
6. **Roman Hájek.** Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). 22st Congress of the European Hematology Association (EHA), 6/2017, Madrid, Spain
7. **Roman Hájek.** Response in an elderly, comorbid RRMM patient ineligible for ASCT, Multiple Myeloma (MM) European Advisory Board, 7/2017, Zurich, Switzerland
8. **Roman Hájek.** Advances in the treatment of myeloma: from clinical trials to everyday practice. 27th Congress of the Polish Society of Hematology and Transfusion Medicine. 9/2017, Warsaw, Poland
9. **Roman Hájek.** Treatment of plasma cell myeloma. State of the art. Conference on Progress in oncology in Gliwice, Poland and worldwide. 10/2017, Gliwice, Poland
10. **Roman Hájek.** Chairman of the Bone marrow transplantology session Conference on Progress in oncology in Gliwice, Poland and worldwide. 10/2017, Gliwice, Poland
11. **Roman Hájek.** Guideline overview, recent changes, and implications for Central Eastern Europe. Multiple Myeloma Expert Forum Meeting. 11/2017, Vienna, Austria

Přednášky (tuzemská konference)

1. **Zdeněk Kořístek**, D.Kaspřák, P.Kovářová, L.Recová, S.Kolářová, M.Pulcer, M.Kořístka, Z.Čermáková, J.Gumulec. Diagnosticko-terapeutická strategie péče o pacienta s podezřením na trombotickou mikroangiopatii. XXIII. Pařízkovy dny, Ostrava, březen 2017
2. **Jana Zuchnická**. Cytologická diagnostika myeloproliferativních onemocnění. XXIII. Pařízkovy dny, Ostrava, březen 2017
3. **Elena Tóthová**. CML a jiné myeloproliferace. XXIII. Pařízkovy dny, Ostrava, březen 2017
4. **Lukáš Stejskal**. Závažné komplikace nových léků v léčbě myeloproliferativních onemocnění. XXIII. Pařízkovy dny, Ostrava, březen 2017
5. **Roman Hájek**. MM. XXIII. Pařízkovy dny, Ostrava, březen 2017
6. **T. Ševčíková** et al. Amyloidózy - identifikace mutací pomocí sekvenování nové generace. XXIII. Pařízkovy dny, Ostrava, březen 2017
7. **K. Growková** et al. Biomarkery u AL amyloidózy. XXIII. Pařízkovy dny, Ostrava, březen 2017
8. **D. Kaspřák**, O. Šimetka, Z. Kořístek, L. Recová, N. Majorosová, P. Kovářová, Z. Čermáková, J. Gumulec. Koordinace diagnostiky a archivace biologického materiálu u pacientů s trombotickými mikroangiopatiemi. XXIII. Pařízkovy dny, Ostrava, březen 2017
9. **Lenka Szeligová**. Frontline treatment of multiple myeloma, Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
10. **Roman Hájek**. Principle of monoclonal gammopathy diagnosis. Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
11. **Kašćák Michal**. What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
12. **Roman Hájek**. New strategy in multiple myeloma: relapse setting, focus on treatment decision in non-responders , role of continuous sequential treatment and minimal residual disease. Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
13. **Roman Hájek**. Principle of modern treatment of Amyloidosis. Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
14. **Roman Hájek**. Case study discussion – optimal model of treatment strategy. Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
15. **Michal Kašćák**, R. Hájek Principles of modern treatment of Morbus Waldenström, Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava
16. **Lenka Szeligová**. Case study discussion: decision-making in frontline treatment. Multiple Myeloma and Amyloidosis Education workshop, 3 a 11/2017, Ostrava

17. **Roman Hájek.** Unmet Need in Multiple Myeloma. Takeda Sympóziium, 4/2017, Mikulov
18. **Roman Hájek.** Lenalidomid v první linii léčby mnohočetného myelomu. Celgene Sympóziium, 4/2017, Mikulov
19. **Roman Hájek.** Léčebná strategie v relapsu onemocnění. OHD 2017, Olomouc, 5/2017
20. **Roman Hájek.** Co-chair of the IMS Educational Workshop, 9/2017, Praha
21. **Roman Hájek.** MGUS & Smoldering Myeloma. How to predict outcome & “To treat or not to treat”. IMS Educational Workshop, Prague, Czech Republic, 9/2017
22. **Roman Hájek.** Understanding where we are going in the field of monoclonal gammopathies. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
23. **Michal Kaščák.** What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
24. **Roman Hájek.** CRAB & high risk SMM. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
25. **Roman Hájek.** Principles of modern treatment of multiple myeloma - first targets, sequential and long-term strategy. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
26. **Roman Hájek.** Principles of modern treatment of amyloidosis. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
27. **Michal Kaščák.** Principles of modern treatment of MorbusWaldenström. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
28. **Tomáš Jelínek.** Immunomodulatory agents, immunotherapy in multiple myeloma checkpoint inhibitors. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
29. **Roman Hájek.** Frontline treatment of multiple myeloma. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
30. **Tomáš Jelínek.** Case study discussion: Decision-making in frontline treatment. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
31. **Roman Hájek.** Treatment strategy in RRMM. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
32. **Roman Hájek.** Case study discussion: Decision-making in relapse treatment. “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies”, 9/2017, Ostrava
33. **Roman Hájek.** Relapsed and/or Refractory Multiple Myeloma treatment landscape across North East Europe. Regional Expert Panel Meeting For Multiple Myeloma, 9/2017, Praha

34. **Hana Plonková**, R. Hájek. Význam laboratorního vyšetření pro diagnostiku a monitorování léčby monoklonálních gamapatií. Prezentace - 3. Ostravské likvorové sympozium, Lékařská fakulta OU, 8.9.2017
35. **Jelinek T**, Paiva B, Hajek R. The role of tumor-associated macrophages in multiple myeloma. 12th myeloma workhshop, Brno, 10/2017.
36. **Tomáš Jelínek**. Detection of MRD in multiple myeloma, Multiple myeloma and amyloidosis Educational workshop, 11/2017
37. **Tomáš Jelínek**, R.Hájek. Immune therapy in multiple myeloma. Multiple Myeloma and Amyloidosis Education workshop, 11/2017, Ostrava
38. **Tomáš Jelínek**, R.Hájek. Utility of multiparameter flow cytometry in plasma cell disorders. Multiple Myeloma and Amyloidosis Education workshop, 11/2017, Ostrava
39. **Michal Šimíček**. New approaches in functional genomics of multiple myeloma. Multiple Myeloma and Amyloidosis Education workshop, 11/2017, Ostrava
40. **Tomáš Jelínek**. Selective inhibitor of nuclear transport: mechanism of action and preclinical data, Farmakoekonomický seminář CMG, 11/2017
41. **Jelinek T**, Hajek R. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Farmakoekonomický seminář CMG, 11/2017
42. **Martina Zatopkova**. Exome sequencing of MRD in multiple myeloma. 12th myeloma workhshop, Brno, 10/2017.
43. **Michal Simicek**. New approaches in functional genomics of multiple myeloma. 12th myeloma workhshop, Brno, 10/2017.
44. **Kaspřák D.**, Kořístek Z., Šimětka O. & Gumulec J. (2017): Prezentace projektu TM. 19th Colours of Sepsis. Ostrava, Česká republika.

Postery:

Postery (zahraniční konference)

1. Barbara Gamberi, Miguel T. Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, **Roman Hajek**, Monique Minnema, Meletios Athanasios Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonio Di Micco, Pamela Bacon, Igor Wolfgang Blau. PS-116 European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT). 16th International Myeloma Workshop, March 1-4, 2017
2. David S. Siegel, Albert Oriol, Peter Rajnics, Jiri Minarik, Vania Hungria, Jae Hoon Lee, Kevin Song, Mihaela Obreja, Sanjay Aggarwal, **Roman Hajek**. PS-254 (d)

- Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). 16th International Myeloma Workshop, March 1-4, 2017
3. Ella Willenbacher, **Roman Hajek**, Thorsten Peters-Regehr, Roman Weger, Wolfgang Willenbacher, Tamas Masszi. PS-260 Use of the Hevylite™ assay as an early predictive tool in MGUS and smoldering myeloma transformation, as well as myeloma relapse: Results from the EU FP7 project OPTATIO. 16th International Myeloma Workshop, March 1-4, 2017
 4. Lucie Brozova, Fedor Kryukov, Jana Filipova, Tereza Sevcikova, Zuzana Kufova, Katerina Growkova, Elena Kryukova, Jan Smetana, Pavel Nemecek, Jiri Jarkovsky, **Roman Hajek**, Michal Simicek. PS-197 Novel approach to study relationship between copy number variation and gene expression in multiple myeloma. 16th International Myeloma Workshop, March 1-4, 2017
 5. Mattia D'Agostino, Andrew Spencer, Pellegrino Musto, Sara Bringhen, Emanuele Angelucci, Fabio Ciceri, Lucio Catalano, Marco Salvini, Anna Baraldi, Sonia Grandi, Alessandro Rambaldi, Alberto Bosi, Iolanda Donatella Vincelli, Paola Omedè, Mariella Grasso, Roberto Marasca, Maria Cantonetti, Annalisa Bernardini, Nicola Cascavilla, Francesca Patriarca, Rossella Troia, Roberto Ria, Anna Marina Liberati, Alessandra Larocca, Tommaso Caravita di Toritto, **Roman Hajek**, Antonio Palumbo, Mario Boccadoro, Francesca Gay. OP-014 Impact of treatment intensification according to patient prognosis: a pooled analysis of 3 randomized phase III trials. 16th International Myeloma Workshop, March 1-4, 2017
 6. Robert Rifkin, Faith Davies, Antonio Palumbo, Jeffrey A. Zonder, Saulius Girnius, Caitlin Costello, Saad Usmani, Jesus Berdeja, Jim Omel, Michael Thompson, J Sanford Schwartz, **Roman Hajek**, EVANGELOS TERPOS, Vania Hungria, Maria-Victoria Mateos, Gordon Cook, xavier leleu, Andrew Spencer, Hartmut Goldschmidt, Brian Seal. PS-142 Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187). 16th International Myeloma Workshop, March 1-4, 2017
 7. Thierry Facon, Jae Hoon Lee, Philippe Moreau, Ruben Niesvizky, Meletios Athanasios Dimopoulos, **Roman Hajek**, Muhtarjan Osman, Sanjay Aggarwal, Zandra Klippel, Jesus San Miguel. OP-044 Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). 16th International Myeloma Workshop, March 1-4, 2017
 8. **Zuzana Kufova, Tereza Sevcikova**, Petr Vojta, **Jana Filipova, Katerina Growkova**, Sebastian Grosicki, Fedor Kryukov, **Roman Hajek**. PS-071 Exome sequencing of AL amyloidosis reveals recurrently mutated genes. 16th International Myeloma Workshop, March 1-4, 2017
 9. David Siegel, Albert Oriol, Peter Rajnics, Jiri Minarik, Vânia Hungria, Jae Hoon Lee, Kevin Song, Mihaela Obreja, Sanjay Aggarwal, **Roman Hajek**. UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). Poster Presentation, 22 Congress of EHA, June 2017, Madrid
 10. **Roman Hajek**, Michel Delforge, Marc Raab, Ludek Pour, Ivan Špička, Evžen Gregora, Jiří Minařík, Sebastian Gonzalez-McQuire, Walter Bouwmeester, Vladimir Maisnar. SURVIVAL STRATIFICATION OF PATIENTS WITH

MULTIPLE MYELOMA (MM) AFTER FIRST RELAPSE: SENSITIVITY ANALYSES OF A NOVEL RISK STRATIFICATION ALGORITHM (RSA). ePoster Presentation, 22 Congress of EHA, June 2017, Madrid

11. **Roman Hájek**, Luděk Pour, Ivan Špička, Muhit Özcan, Vladimír Maisnar, Mehmet Turgut, Long Kwei, Zeena Salman, Elizabeth Bilotti, Albert Oriol. INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA. Poster Presentation, 22 Congress of EHA, June 2017, Madrid
12. Evangelos Terpos, Nadjoua Maouche, Jiri Minarik, Eirini Katodritou, Matthew W Jenner, **Hana Plonkova**, Maria Gavriatopoulou, Grant Vallance, Tomas Pika, Maria Kotsopoulou, Jaimal Kothari, **Tomas Jelinek**, Efsthios Kastritis, Robin Aitchison, Meletios A. Dimopoulos, Karthik Ramasamy and **Roman Hajek**. "Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases. Poster - Poster presentation at the 59th Annual Meeting and Exposition (December 9-12, 2017), ASH 2017 Atlanta
13. **Jaromir Gumulec**, Václav Procházka, Tomáš Jonszta, Daniel Czerný, Martin Roubec, Jirka Mačák, Petra Kovářová, Ivo Lochman, **David Kaspřák**, and **Roman Hajek**. The Role of VWF, FVIII, ADAMTS13 and Inflammatory Response in the Outcome of Acute Ischemic Stroke Mechanical Thrombectomy Procedure. ASH 2017 (December 9-12, 2017)
14. **Kufová Z, Growková K, Vojta P, Filipová J, Simicek M, Jelinek T, Zatopkova M, Grosicki S, Mikulasova A, Hajduch N, Pour L, Stork M, Sevcikova T, Hajek R**. Whole Exome Sequencing of Plasma Cells Precancerous MGUS and Malignant AL Amyloidosis Reveals Small Number of Shared Mutated Genes. Poster - Poster presentation at the 59th Annual Meeting and Exposition (December 9-12, 2017), ASH 2017 Atlanta
15. Meletios A. Dimopoulos, Efsthios Kastritis, **Roman Hajek**, Luca Dozza, Meral Beksac, Alessandra Larocca, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Sonja Zweegman, Heinz Ludwig, Lucia Pantani, Andrew Spencer, Anna Pascarella, Marina Martello, Susana Carvalho, Hlif Steingrimsdottir, Claudia Cellini, Petra Cornelisse, Rossella Troia, Patrizia Tosi, Bronno van der Holt, Mario Boccadoro, Pieter Sonneveld, and Michele Cavo. Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients : An Analysis of the Prospective Randomized EMN02/HO95 Study. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
16. Heinz Ludwig, Wolfram Pönisch, Alexander Egle, Stefan Knop, Martin Schreder, Daniel Lechner, **Roman Hajek**, Eberhard Gunsilius, Michael A. Fridrik, Andreas Petzer, Katja Weisel, Dietger Niederwieser, Axel Hinke, Richard Greil, and Niklas Zojer. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
17. **Tomas Jelinek**, Aintzane Zabaleta, Cristina Perez, Daniel Ajona, Diego Alignani, Idoia Rodriguez, Sonia Garate, Sarai Sarvide, Marta Lasa, Patricia Maiso, Felipe Prosper, **Roman Hajek**, Jesus F. San Miguel, and Bruno Paiva. Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML). Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
18. Paul G Richardson, Jesus F. San Miguel, Philippe Moreau, **Roman Hajek**, Meletios A. Dimopoulos, Antonio Palumbo, Katarina Luptakova, Tomas Skacel, Shaji K. Kumar, and Kenneth C. Anderson. Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta

19. Katja Weisel, David Siegel, Jesus F. San Miguel, **Roman Hájek**, P. Joy Ho, Gianluca Gaidano, Robert Z. Orlowski, Lifen Zhou, Amy S. Kimball and Philippe Moreau. Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
20. Ivan Spicka, Enrique M. Ocio, Heather E. Oakervee, Richard Greil, Raymond H. Banh, Laurence Catley, Shang-Yi Huang, James M. D'Rozario, Meletios A. Dimopoulos, José Rodríguez, Sara Martínez, Sonia Extremera, Vicente Alfaro, Angelo Michele Carella, Nathalie Meuleman, **Roman Hájek**, Argiris Symeonidis, Chang-Ki Min, Paul Cannell, Heinz Ludwig, Pieter Sonneveld, and Maria V. Mateos. Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
21. **Kaspřák D., Kořístek Z., Navrátil M., Richterová P. & Gumulec J.** (2017): The next case report of thrombotic thrombocytopenic purpura (TTP) after influenza vaccination [poster]. International Meeting for the Thrombosis and Hemostasis Community. Berlín, Německo.
22. **Kaspřák D., Kořístek Z., Šimetka O., Šuláková T. & Gumulec J.** (2017): Centrum pro trombotické mikroangiopatie Ostrava [poster] (oceněn). 6. Košické hematologické a transfuziologické dny. Košice, Slovensko.

Postery (tuzemská konference)

1. **Tereza Ševčíková**, Fedor Kryukov, Lucie Brožová, **Jana Filipová, Zuzana Kufová, Kateřina Growková**, Renata Bezděková, Pavel Němec, Lucie Řihová, Jiří Jarkovský, and **Roman Hájek**. AIMS Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression. Pařízkovy dny 2017, Ostrava
2. **Kaspřák D., Kořístek Z., Navrátil M., Šimetka O., Richterová P. & Gumulec J.** (2017): Vybrané případy trombotické mikroangiopatie z klinické praxe Kliniky hematologie, Fakultní nemocnice Ostrava. XXIV. Česko-Slovenská konference o trombóze a hemostáze [poster] (oceněn). Hradec Králové, Česká republika.

Abstrakta:

1. Barbara Gamberi, Miguel T. Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, **Roman Hájek**, Monique Minnema, Meletios Athanasios Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonio Di Micco, Pamela Bacon, Igor Wolfgang Blau. PS-116 European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT). 16th International Myeloma Workshop, March 1-4, 2017
2. David S. Siegel, Albert Oriol, Peter Rajnics, Jiri Minarik, Vania Hungria, Jae Hoon Lee, Kevin Song, Mihaela Obreja, Sanjay Aggarwal, **Roman Hájek**. PS-254 (d) Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). 16th International Myeloma Workshop, March 1-4, 2017

3. Ella Willenbacher, **Roman Hajek**, Thorsten Peters-Regehr, Roman Weger, Wolfgang Willenbacher, Tamas Masszi. PS-260 Use of the Hevylite™ assay as an early predictive tool in MGUS and smoldering myeloma transformation, as well as myeloma relapse: Results from the EU FP7 project OPTATIO. 16th International Myeloma Workshop, March 1-4, 2017
4. Lucie Brozova, Fedor Kryukov, Jana Filipova, Tereza Sevcikova, Zuzana Kufova, Katerina Growkova, Elena Kryukova, Jan Smetana, Pavel Nemec, Jiri Jarkovsky, **Roman Hajek**, Michal Simicek. PS-197 Novel approach to study relationship between copy number variation and gene expression in multiple myeloma. 16th International Myeloma Workshop, March 1-4, 2017
5. Mattia D'Agostino, Andrew Spencer, Pellegrino Musto, Sara Bringhen, Emanuele Angelucci, Fabio Ciceri, Lucio Catalano, Marco Salvini, Anna Baraldi, Sonia Grandi, Alessandro Rambaldi, Alberto Bosi, Iolanda Donatella Vincelli, Paola Omedè, Mariella Grasso, Roberto Marasca, Maria Cantonetti, Annalisa Bernardini, Nicola Cascavilla, Francesca Patriarca, Rossella Troia, Roberto Ria, Anna Marina Liberati, Alessandra Larocca, Tommaso Caravita di Toritto, **Roman Hajek**, Antonio Palumbo, Mario Boccadoro, Francesca Gay. OP-014 Impact of treatment intensification according to patient prognosis: a pooled analysis of 3 randomized phase III trials. 16th International Myeloma Workshop, March 1-4, 2017
6. Robert Rifkin, Faith Davies, Antonio Palumbo, Jeffrey A. Zonder, Saulius Girnius, Caitlin Costello, Saad Usmani, Jesus Berdeja, Jim Omel, Michael Thompson, J Sanford Schwartz, **Roman Hajek**, EVANGELOS TERPOS, Vania Hungria, Maria-Victoria Mateos, Gordon Cook, xavier leleu, Andrew Spencer, Hartmut Goldschmidt, Brian Seal. PS-142 Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187). 16th International Myeloma Workshop, March 1-4, 2017
7. Thierry Facon, Jae Hoon Lee, Philippe Moreau, Ruben Niesvizky, Meletios Athanasios Dimopoulos, **Roman Hajek**, Muhtarjan Osman, Sanjay Aggarwal, Zandra Klippel, Jesus San Miguel. OP-044 Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). 16th International Myeloma Workshop, March 1-4, 2017
8. Zuzana Kufova, Tereza Sevcikova, Petr Vojta, Jana Filipova, Katerina Growkova, Sebastian Grosicki, Fedor Kryukov, **Roman Hajek**. PS-071 Exome sequencing of AL amyloidosis reveals recurrently mutated genes. 16th International Myeloma Workshop, March 1-4, 2017
9. David Siegel, Albert Oriol, Peter Rajnics, Jiri Minarik, Vânia Hungria, Jae Hoon Lee, Kevin Song, Mihaela Obreja, Sanjay Aggarwal, **Roman Hajek**. UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). Poster Presentation, 22 Congress of EHA, June 2017, Madrid
10. **Roman Hajek**, Michel Delforge, Marc Raab, Ludek Pour, Ivan Špička, Evžen Gregora, Jiří Minařík, Sebastian Gonzalez-McQuire, Walter Bouwmeester, Vladimir Maisnar. SURVIVAL STRATIFICATION OF PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER FIRST RELAPSE: SENSITIVITY ANALYSES OF A NOVEL RISK STRATIFICATION ALGORITHM (RSA). ePoster Presentation, 22 Congress of EHA, June 2017, Madrid
11. **Roman Hájek**, Luděk Pour, Ivan Špička, Muhit Özcan, Vladimír Maisnar, Mehmet Turgut, Long Kwei, Zeena Salman, Elizabeth Bilotti, Albert Oriol. INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA. Poster Presentation, 22 Congress of EHA, June 2017, Madrid
12. **Roman Hajek**, Michel Delforge, Marc Raab, Jakub Radocha, Jan Straub, Walter Bouwmeester, Zsolt Szabo, Ludek Pour, Sebastian Gonzalez-McQuire, Vladimir Maisnar. RISK STRATIFICATION ALGORITHM USING REAL-WORLD DATA FROM

PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): DESCRIPTION OF CLINICAL OUTCOME BY TREATMENT REGIMEN. 22 Congress of EHA, June 2017, Madrid

13. Weisel K. C., Miguel J. S., Cook, G, Leiba, M, Suzuki, K, Kumar, S, Cavo, M (Cavo, Michele); Avet-Loiseau, H (Avet-Loiseau, Herve); Quach, H (Quach, Hang); Hungria, V (Hungria, Vania); Lentzsch, S (Lentzsch, Suzanne); **Hajek, R** (Hajek, Roman); Sonneveld, P (Sonneveld, Pieter); Wu, K (Wu, Kaida)...More...Less Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, June 2017
14. Stoklasova, M; Drevojankova, B; Burdova, A ; Sablaturova, I ; Strnkova, A; Truhlikova, L; Lencesova, Z; Kucharova, H; Brychtova, Y; Panovska, A; Plevova, K; Oltova, A; Mayer, J; Doubek, M; Pospisilova, S; Rytikova, N; Adamova, D; Zygulova, I; Heinzova, V; Zuchnicka, J; **Duras, J** et al. Rare recurrent chromosomal abnormalities in CLL detected by conventional cytogenetics stimulated by CpG ODN & IL 2 and FISH. MOLECULAR CYTOGENETICS, Meeting Abstract Published: JUN 29 2017 Volume: 10, Supplement: 1
15. Evangelos Terpos, Nadjoua Maouche, Jiri Minarik, Eirini Katodritou, Matthew W Jenner, **Hana Plonkova**, Maria Gavriatopoulou, Grant Vallance, Tomas Pika, Maria Kotsopoulou, Jaimal Kothari, **Tomas Jelinek**, Efsthios Kastritis, Robin Aitchison, Meletios A. Dimopoulos, Karthik Ramasamy and **Roman Hajek**. "Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases. Poster - Poster presentation at the 59th Annual Meeting and Exposition (December 9-12, 2017), ASH 2017 Atlanta
16. **Jaromir Gumulec**, Václav Procházka, Tomáš Jonszta, Daniel Czerný, Martin Roubec, Jirka Mačák, Petra Kovářová, Ivo Lochman, **David Kaspřák**, and **Roman Hajek**. The Role of VWF, FVIII, ADAMTS13 and Inflammatory Response in the Outcome of Acute Ischemic Stroke Mechanical Thrombectomy Procedure. ASH 2017 (December 9-12, 2017)
17. **Kufová Z, Growková K, Vojta P, Filipová J, Simicek M, Jelinek T, Zatopkova M, Grosicki S, Mikulasova A, Hajduch N, Pour L, Stork M, Sevcikova T, Hajek R**. Whole Exome Sequencing of Plasma Cells Precancerous MGUS and Malignant AL Amyloidosis Reveals Small Number of Shared Mutated Genes. Poster - Poster presentation at the 59th Annual Meeting and Exposition (December 9-12, 2017), ASH 2017 Atlanta
18. Meletios A. Dimopoulos, Efsthios Kastritis, **Roman Hajek**, Luca Dozza, Meral Beksac, Alessandra Larocca, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Sonja Zweegman, Heinz Ludwig, Lucia Pantani, Andrew Spencer, Anna Pascarella, Marina Martello, Susana Carvalho, Hlif Steingrimsdottir, Claudia Cellini, Petra Cornelisse, Rossella Troia, Patrizia Tosi, Bronno van der Holt, Mario Boccadoro, Pieter Sonneveld, and Michele Cavo. Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients : An Analysis of the Prospective Randomized EMN02/HO95 Study. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
19. Heinz Ludwig, Wolfram Pönisch, Alexander Egle, Stefan Knop, Martin Schreder, Daniel Lechner, **Roman Hajek**, Eberhard Gunsilius, Michael A. Fridrik, Andreas Petzer, Katja Weisel, Dietger Niederwieser, Axel Hinke, Richard Greil, and Niklas Zojer. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
20. **Tomas Jelinek**, Aintzane Zabaleta, Cristina Perez, Daniel Ajona, Diego Alignani, Idoia Rodriguez, Sonia Garate, Sarai Sarvide, Marta Lasa, Patricia Maiso, Felipe Prosper, **Roman Hajek**, Jesus F. San Miguel, and Bruno Paiva. Pre-Clinical Efficacy of the Anti-

- CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML). Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
21. Paul G Richardson, Jesus F. San Miguel, Philippe Moreau, **Roman Hajek**, Meletios A. Dimopoulos, Antonio Palumbo, Katarina Luptakova, Tomas Skacel, Shaji K. Kumar, and Kenneth C. Anderson. Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
 22. Katja Weisel, David Siegel, Jesus F. San Miguel, **Roman Hájek**, P. Joy Ho, Gianluca Gaidano, Robert Z. Orlowski, Lifan Zhou, Amy S. Kimball and Philippe Moreau. Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
 23. Ivan Spicka, Enrique M. Ocio, Heather E. Oakervee, Richard Greil, Raymond H. Banh, Laurence Catley, Shang-Yi Huang, James M. D'Rozario, Meletios A. Dimopoulos, José Rodríguez, Sara Martínez, Sonia Extremera, Vicente Alfaro, Angelo Michele Carella, Nathalie Meuleman, **Roman Hájek**, Argiris Symeonidis, Chang-Ki Min, Paul Cannell, Heinz Ludwig, Pieter Sonneveld, and Maria V. Mateos. Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma. Program: Oral and Poster Abstracts. (December 9-12, 2017), ASH 2017 Atlanta
 24. **Zuzana Kufova, Katerina Growkova, Petr Vojta, Jana Filipova, Michal Simicek, Tomas Jelinek, Martina Zatopkova, David Kasprak, Marian Hajduch, Ludek Pour, Martin Stork, Tereza Sevcikova, Roman Hajek.** Whole exome sequencing of plasma cells in monoclonal gammopathies reveals heterogeneity and small number of shared mutated genes. Plzeň
 25. **Kateřina GROWKOVÁ, Reuben TOOZE, Michal ŠIMÍČEK, Roman HÁJEK.** IN VITRO ŘÍZENÁ DIFERENCIACE PLASMATICKÝCH BUNĚK MNOHOČETNÉHO MYELOMU. SVK, LF OU Ostrava, 2017
 26. **KATERINA GROWKOVA, MICHAL SIMICEK, ROMAN HAJEK.** NEW APPROACHES IN FUNCTIONAL GENOMICS OF MULTIPLE MYELOMA 12th myeloma workshp, Brno, 10/2017.
 27. L. RIHOVA, R. BEZDEKOVA, M. STEJSKALOVA, R. KRALOVA, B. SMRZOVA, R. SUSKA, M. PENKA, **R. HAJEK.** POSSIBILITIES OF FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA. 12th myeloma workshp, Brno, 10/2017.
 28. **M. ZATOPKOVA, J. FILIPOVA., T. JELINEK, P. VOJTA, T. ŠEVČIKOVA, L. ŘIHOVA, K. GROWKOVA, Z. KUFOVA, R. BEZDĚKOVA, M. ŠIMICEK, J. SMEJKALOVA, M. HAJDUCH, L. POUR, J. MINAŘIK, A. JUNGOVA, V. MAISNAR, F. KRYUKOV, R. HAJEK.** EXOME SEQUENCING OF MULTIPLE MYELOMA IN STAGE OF MINIMAL RESIDUAL DISEASE. 12th myeloma workshp, Brno, 10/2017.
 29. **T. JELINEK, B. PAIVA, R. HAJEK.** THE ROLE OF TUMOR ASSOCIATED MACROPHAGES (TAMS) IN MULTIPLE MYELOMA (MM). 12th myeloma workshp, Brno, 10/2017.
 30. **Kořístek, Zdeněk, Gumulec, Jaromír, Kaspřák, David, Šimetka, Ondřej,** Trombotická mikroangiopatie - proč je důležité ji nepodceňovat? Interní medicína pro praxi (Print). 2017, roč. 19, Suppl. A (XII. interní medicína pro praxi, VIII. Olomouc kazuistická konference ambulantních internistů, Olomouc, 23. - 24. března 2017), s. 14. ISSN: 1212-7299.
 31. Buske, C; Sadullah, S; Kastritis, E; Tedeschi, A; Garcia-Sanz, R; Bolkun, L; Leleu, X; Willenbacher, W; **Hajek, R;** Minnema, MC; Cheng, M; Graef, T; Dimopoulos, MA. Treatment and outcome patterns in patients with relapsed Waldenstrom Macroglobulinemia from a large observational Pan-European data platform. ONCOLOGY RESEARCH AND TREATMENT. 2017 Sep;40(3): 119-120. 1,667